Since the introduction of the UK National Health Service Breast Screening Programme (NHSBSP) in 1988, there has been a large increase in the incidence of ductal carcinoma *in situ* (DCIS). Thus, in the year before the introduction of screening ([@bib18]), 295 cases of DCIS were recorded in England and Wales, in women aged 50--64, while 2500 cases were detected, by screening, in the year 2008/2009 ([@bib17]), DCIS now accounts for around 20% of screen-detected breast cancers ([@bib4], [@bib17]; [@bib25]). One of the main reasons for this increase is that DCIS is relatively easy to detect on a mammogram owing to the micro-calcification that is frequently present ([@bib14]). Fewer cases of DCIS present symptomatically as about 80% of cases are nonpalpable and diagnosed by mammography alone ([@bib13]; [@bib25]). However, it is worthy of note that, in 2006, in England, 40% of DCIS presented outside the national screening programme ([@bib16]). The increase in the incidence of DCIS and the uncertainty about its propensity to become malignant, if left untreated, have led to discussions about overdiagnosis ([@bib27]; [@bib7]). These are not just confined to noninvasive breast cancer, and the arguments about overdiagnosis in screening, in general ([@bib28]; [@bib3]; [@bib7]), partly revolve around length of follow-up as the benefits of screening persist over many years.

The lack of clarity regarding treatment options, and the increasing trend in the US to treat DCIS with bilateral mastectomy ([@bib24]) also raises the spectre of overtreatment. The very earliest study of untreated DCIS was confined to a small number of low-grade cases, with a 39% (11 of 28) conversion to invasive disease after a median follow-up of 31 years ([@bib20]), but an overview in 2006 ([@bib13]), reported rates varying from 14 to 75%. Recurrence rates in both the randomised trials and observational studies are very variable. The overview by Mokbel ([@bib13]) reports recurrence rates of 1.5% after mastectomy, 33--56% after conservation alone and 3 to 19% after conservation with radiotherapy, but the studies contributing to these figures have a wide range of follow-up (median follow-up 57 to 120 months).

Whereas there is uniform agreement regarding the importance of age and a clear margin (even if there is no agreement as to the definition of 'clear\') for reducing recurrence, the literature is divided as to whether biological factors (size and grade) are as predictive ([@bib27]; [@bib25]). Solin found that grade was important after 5 years but not at 10 years ([@bib23]). Harris\' accompanying editorial concludes that longer-term follow-up is important particularly, if looking for specific types of DCIS where minimal treatment could be considered ([@bib5]).

Estimates of the rate of recurrence, as invasive disease, range from between one-third and one-half, and there is minimal data on features predicting invasive as opposed to noninvasive recurrence. An invasive recurrence is clearly predictive for the development of metastatic disease and subsequent mortality ([@bib13]).

We present a minimum of 11-years follow-up (median 183 months, range 133 months to 259 months) of a cohort of screen-detected DCIS cases diagnosed between April 1988 and March 1999; all graded retrospectively, by one expert pathologist.

Materials and methods
=====================

The study population consisted of 840 cases of noninvasive breast cancer without evidence of invasive disease recorded between 1 March 1988 and 31 March 1999 on the National Breast Screening Computer System in 10 West Midlands breast screening services. 674 cases were DCIS alone, and 144 were DCIS with micro-invasion or possible micro-invasion. Of the remaining cases, 15 were lobular carcinoma *in situ* and 7 were Paget\'s disease of the breast. All cases were allocated a study ID number, and their demographic details were entered on to the study database. Diagnosis, treatment and follow-up data, recorded for these cases on the cancer registration database and in-patient case notes held by the West Midlands Cancer Intelligence Unit (WMCIU), were added to the study database. At this stage, 71 cases were excluded (35 were not DCIS, 10 were bilateral, 15 were second primary breast cancers and 11 were recurrences) ([Figure 1](#fig1){ref-type="fig"}).

Data not available at the WMCIU were sought in and abstracted from the original case notes stored at the treating hospitals, using a specialist data collection proforma. A pathological slide review was undertaken by a consultant pathologist to provide consistent information on diagnostic characteristics. The slides had patient identifiers obscured to ensure anonymity. Furthermore, to deal with the potential problem of the review pathology being significantly different from the original pathology, a comprehensive double-blinding process (under the terms of Multi-centre Research Ethics Committee approval) was used throughout the project. Once the data collection process was complete, the double-blinding process was applied to the completed database. It was then possible to link, on a case-by-case basis, data from the treatment and follow-up review with data derived from the slide review, while ensuring that it was impossible to identify individuals. 123 cases were excluded from the pathology review and 37 from the case note review, owing to problems with slide and case note availability. A further 32 cases were excluded following pathology and case note review, because they were found not to be DCIS (8 had invasive disease, 2 cases were node positive, although no invasive disease was found in the original resection, 10 had benign disease and 11 were LCIS cases), and one because it was detected symptomatically rather than through screening. After the exclusions, 700 cases were identified with a full-treatment dataset, 614 cases were subjected to a full pathology review, and 597 cases had both pathology and treatment datasets ([Figure 1](#fig1){ref-type="fig"}).

To maximise the number of 'known\' data items, information relating to margin status, nuclear grade and tumour size was obtained from the original pathology reports and from the pathology review. For margin status, the margin size was taken from the original report, if the actual distance was stated. If this was not the case, the distance measured in the pathology review was used. If the actual distance was not available from either source, a descriptive margin status (e.g. 'clear\') was used. If no information on margin status was available from either source, the margin status was recorded as unknown. For tumour size, the size from the pathology review was used in preference to that in the original pathology report, to maximise consistency. If tumour size was not available from either source, the size was recorded as unknown. The nuclear grade was also preferentially taken from the pathology review data. If nuclear grade was not available from either source, the nuclear grade was recorded as unknown.

Cases were followed up to 30 June 2010 via the WMCIU. Local and regional recurrences and distant metastatic events, along with date of death and underlying cause of death, were identified from the WMCIU\'s cancer registration database. Invasive recurrences, after a first primary diagnosed as DCIS, are registered as multiple primary cancers in their own right.

Statistical analyses were performed using SPSS (Version 13.0, SPSS Inc., Chicago, IL, USA), Statistica (Statsoft Ltd, Tulsa, OK, USA) and Microsoft Excel (Microsoft Corp., Seattle, WA, USA). *χ*^2^ tests, with Bonferonni corrections for multiple testing, where appropriate, compared use of adjuvant therapy between patients treated with conservative surgery and those treated by mastectomy, and between patients with clear and with involved excision margins. Numbers of recurrences were compared using *χ*^2^ tests between patients with different treatments, margins, grades and Van Nuys Prognostic Index (VNPI). Recurrence rates were compared for these groups using a Kaplan--Meier chart and a log-rank test, and times to recurrence using a *t*-test. All events including censored cases were included in the Kaplan--Meier plots and analysis.

Multivariate Cox regression was utilised to determine significant factors related to recurrence.

Results
=======

Pathological characteristics
----------------------------

As shown in [Table 1](#tbl1){ref-type="table"}, for the 700 cases with a full treatment data set, micro-calcification was present in a high proportion of cases (74.3%); moderate or severe necrosis (\>5%) was visible in 51.3% of cases; and 49.1% of cases were of high nuclear grade. Tumour size was recorded for 57.9% of cases. In the majority of cases with known tumour size (65.4%), the DCIS was 15 mm or less in diameter; in only 1% of cases was the diameter greater than 40 mm. An exact distance to the nearest tumour margin was available for 42.6% of cases and some description of margin status was available for 90.7%.

The VNPI calculation depends on lesion size, margin width, and a classification based on nuclear grade and necrosis ([@bib21]). At least one of the required data items was missing from 347 cases, so a VNPI score could only be calculated for 353 cases (50.4%). Of these, 81 (22.9%) were in the best prognostic groups (VNPI score 3 or 4); 255 (72.2%) had a VNPI score of 5, 6 or 7; and 17 (4.8%) had a VNPI score of 8. No lesions had a VNPI score of 9.

Treatment data
--------------

[Table 2](#tbl2){ref-type="table"} summarises the surgical and adjuvant treatment received. 449 cases (64.2%) had breast-conserving surgery as their final therapeutic operation and 251 (35.8%) had a mastectomy. Overall, a significantly higher proportion of cases treated with breast-conserving surgery (289 cases, 64.3%) received adjuvant therapy compared with cases treated with mastectomy (108 cases, 42.8% *P*\<0.00001). 143 cases treated with breast-conserving surgery (31.7%) received adjuvant radiotherapy compared with only four cases treated with mastectomy (1.6% *P*\<0.00001). Patients treated with mastectomy were more likely to receive hormone therapy as their only adjuvant treatment (104, 41.6%) than those treated with conservative surgery (144, 32.1%). This tended towards significance but was not the case when corrections for multiple testing were applied. However, patients treated with breast-conserving surgery were more likely to receive hormone therapy (252, 56.0%) than patients who had a mastectomy (106, 42.4% *P*\<0.0005). Of the 358 patients receiving hormone therapy, 10 (2.8%) reported stopping treatment within 2 months.

Follow-up
---------

[Table 3](#tbl3){ref-type="table"} shows the number and type of first ipsilateral and metastatic events, and number and cause of deaths up to 30 June 2010, and splits these according to the initial grade of the DCIS. After a median follow-up of 183 months (range 133 to 259 months), 102 (14.6%) first-isolated local recurrences in the ipsilateral breast and 4 local recurrences with contra-lateral disease 106 (15.1%) were identified. 49 (48%) of the isolated local recurrences were invasive and eventually 54 (50.1%) of the 106 developed invasive disease in the ipsilateral breast. A further seven women presented with metastases.

37 contra-lateral events were recorded; 30 (81%) were invasive. Life tables ([Table 4](#tbl4){ref-type="table"}) constructed to examine ipsilateral and first metastatic events show that, at 60 months, the cumulative proportion developing recurrence was 8.6% (HR=0.0004, *n*=613). At 180 months, the recurrence rate almost doubled to 16% (HR 0.0016 *n*=255). Age, size, grade, margin, and necrosis were not predictive for recurrence either singly or in multi-variant analysis.

For women treated with breast-conserving surgery at 60 months, the cumulative proportion-developing reoccurrence was 11.8% (HR 0.0002, *n*=379); by 180 months, this rose to 21.5% (HR 0.002, *n*=166). Tumour size is the only single predictor. For those treated by mastectomy, the cumulative proportion developing recurrence at 60 months was 3.1% (HR 0.0007, *n*=234); by 180 months, this was 8% (HR 0.001, *n*=89). Tumour size and necrosis tend to significance but less than for breast-conserving surgery (*P*=0.08).

Time to recurrence
------------------

Of those with known original DCIS grade, median time to first local non contra-lateral event was 15 months for noninvasive recurrence, regardless of original DCIS grade. Overall, the median time to invasive recurrence was 60 months. This was grade dependent. Median time to invasive recurrence from initially high-grade DCIS was 76 months, and from low-/intermediate-grade DCIS was 131 months ([Figure 2](#fig2){ref-type="fig"}). Median time for metastasis, as first event, was 82 months (range 15 to 188 months).

The histological grades of the invasive recurrences, which were not centrally reviewed, are documented in [Table 5](#tbl5){ref-type="table"}. The numbers are small but no high-grade invasive disease arose from low-grade DCIS, and, of the 28 invasive recurrences (of known grade) arising from intermediate or high-grade DCIS, only one was grade 1.

In total, 108 (15.4%) women died before 30 June 2010. Twenty Five (3.6%) died from breast cancer ([Table 5](#tbl5){ref-type="table"}). There were no breast cancer deaths in the low-grade DCIS group, and similar rates in the intermediate (3.4%) and the high (3.2%)-grade groups. The majority of the deaths (82/108; 76%) were unrelated to the women\'s breast cancer diagnosis. Of the 54 cases with an ipsilateral invasive recurrence, 18 had died of breast cancer by the census date. Of the cases who died of breast cancer, 70% had involved, or unknown margin status compared with 35.3% of the cases, who were still alive.

Discussion
==========

At 15.1% (including those with bilateral disease) (cumulatively 21.5% after breast-conserving surgery and 8% post mastectomy), the overall first local recurrence rates from this observational cohort are well within the ranges quoted in the two recent overviews ([@bib13]; [@bib25]). What is important to note is that events continue to occur throughout the 259 months of follow-up. For women treated by breast-conserving surgery, the rate almost doubles between 60 and 180 months and it more than doubles over the same time period for women treated by mastectomy, indicating that event rates do not drop or stabilise with time. This suggests that the 'cure\' model ([@bib10]) that has been applied to invasive cancers is not applicable to DCIS and that standard short term follow-up will miss a significant number of events.

Our finding that, after 183 months, the absolute ipsilateral event rates are not DCIS grade dependent is in keeping with [@bib22] (median follow-up 9.4 yr range 1--19 yrs) but contradicts [@bib1] (5.4 yrs), [@bib15] (105 months), [@bib9] (77.9 months) and [@bib19] (5.7 yrs). [@bib1] and [@bib9] did not find that the type of recurrence (i.e. invasive or noninvasive was related to the original DCIS grade, but [@bib1]) does report that the development of metastatic disease is strongly associated with high-grade DCIS, as in our series.

Our long period of follow-up has enabled us to look at type and timing of first recurrence and relate this to original DCIS grade. Noninvasive recurrence occurs early and this is not dependent on the original grade of the DCIS. In contrast, invasive local recurrence not only presents later, but the median time is DCIS grade dependent too.

High-grade DCIS starts to recur early (under 6 months) and continues throughout the period of follow-up, with a median time of 76 months, whereas low/intermediate grade DCIS only starts to recur after 60 months (most of the noninvasive events have occurred by this point), with a median time of 131 months. Only [@bib22] have reported time to local recurrence, and he found no statistical difference between median time to invasive recurrence (4.8 years) and noninvasive recurrence (5.1 years).

As expected there have been few deaths in our DCIS cohort, but, in line with [@bib11] and [@bib26], these deaths have been in those women who either presented with metastatic disease as their first event, or had an ipsilateral invasive recurrence as their first or subsequent events. To date we have not identified any high-grade recurrences, metastatic events or deaths from our cohort of 68 low-grade DCIS patients. This is in keeping with [@bib15] who also showed lower local recurrence rates and no deaths in his low-grade population. Of those patients with an ipsilateral invasive recurrence who had died by the study census date, 70% had involved or unknown margin status compared with only 35.3% of those who were still alive.

The main limitation of this study is that it is a cohort of women over 50 years of age with mixed, uncontrolled treatment. As in other studies from the period, we have limited information on margin status that cannot be fully resolved by pathological review ([@bib1]; [@bib19]) reflecting the more variable pathological practice encountered earlier in the UK screening programme. The grade distribution (49% high grade and 10% low grade) is clearly different to the EORTC randomised trial (40% poorly and 32% well-differentiated) ([@bib1]), which had higher rates of low-grade/well-differentiated DCIS (however, this trial recruited both clinically and mammographically detected DCIS treated by conservation surgery) and to the UKCCCR/ANZ (75% high and 7% low grade) ([@bib11]). The distribution is not that different to the current UK data from the *NHSBSP/ABS 2010* audit of screen-detected cancers (58% high grade and 10% low grade). An advantage of our study is that central pathological review by a single expert does provide uniformity and excludes cases that have been under or over reported by local pathologists ([@bib15]; [@bib19]).

The long follow-up in the present study supports the concept that DCIS is a long-term risk factor that will bias studies of overdiagnosis with short-term follow-up. The differential effect of DCIS grade on type of recurrence and time to invasive recurrence supports the model suggesting that breast cancer evolves along two distinct molecular genetic pathways ([@bib12]; [@bib2]), particularly as we have not identified any high-grade recurrences, metastatic events or deaths from our cohort of low-grade DCIS.

It would be nice to try and use our data as a basis to calculate or recalculate overdiagnosis rates from DCIS ([@bib6]), but all of these women received surgical treatment and many had additional radiotherapy that is not the same as leaving them untreated. The low event rates over a prolonged time reinforce the rationale for aggressive treatment of younger women who have higher event rates ([@bib8]) compared with older women. Whether the same treatment policies should be used for older women who could well outlive their disease, or women with low-grade DCIS, is open for debate. We are aware of discussion about a randomised trial comparing conventional surgical treatment with active radiological monitoring and we consider our data support this approach.

This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License.

![STARD diagram showing case numbers.](bjc2012151f1){#fig1}

![Time to first recurrence (invasive and noninvasive) according to original grade.](bjc2012151f2){#fig2}

###### Pathology characteristics of the 700 cases with treatment data using data from the pathology review and original pathology reports for micro-calcification, necrosis, nuclear grade, tumour size and margin

                         **All cases**         **VNPI groups**   **Conservation surgery (CS)**   **VNPI groups**   **Mastectomy (MX)**   **VNPI groups**                                             
  ---------------------- --------------------- ----------------- ------------------------------- ----------------- --------------------- ----------------- ------- ----- ------- ----- ------- ----- -------
  Microcalcification     Present               520               74.29                                                                   324               72.16                 196   78.09          
                         Not present           76                10.86                                                                   51                11.36                 25    9.96           
                         Unknown               104               14.86                                                                   74                16.48                 30    11.95          
                                                                                                                                                                                                      
  Necrosis               None                  165               23.57                                                                   108               24.05                 57    22.71          
                         \<5%                  63                9.00                                                                    37                8.24                  26    10.36          
                         5--50%                188               26.86                                                                   119               26.50                 69    27.49          
                         \>50%                 171               24.43                                                                   105               23.39                 66    26.29          
                         Unknown               113               16.14                                                                   80                17.82                 33    13.15          
                                                                                                                                                                                                      
  Nuclear grade          Low                   68                9.71                                                                    47                10.47                 21    8.37           
                         Intermediate          174               24.86                                                                   112               24.94                 62    24.70          
                         High                  344               49.14                           344               49.14                 210               46.77   210   46.77   134   53.39   134   53.39
                         Unknown               114               16.29                           114               16.29                 80                17.82   80    17.82   34    13.55   34    13.55
                         Non-high+necrosis     124               17.71                           124               17.71                 78                17.37   78    17.37   46    18.33   46    18.33
                         Non-high - necrosis   118               16.86                           118               16.86                 81                18.04   81    18.04   37    14.74   37    14.74
                                                                                                                                                                                                      
  Original tumour size   \<5 mm                31                4.43                                                                    23                5.12                  8     3.19           
                         5--10 mm              110               15.71                           265               37.86                 97                21.60   208   46.33   13    5.18    57    22.71
                         11--15 mm             124               17.71                                                                   88                19.60                 36    14.34          
                         16--20 mm             91                13.00                                                                   65                14.48                 26    10.36          
                         21--30 mm             41                5.86                            136               19.43                 18                4.01    85    18.93   23    9.16    51    20.32
                         31--40 mm             4                 0.57                                                                    2                 0.45                  2     0.80           
                         \>40 mm               4                 0.57                            4                 0.57                  3                 0.67    3     0.67    1     0.40    1     0.40
                         Unknown               295               42.14                           295               42.14                 153               34.08   153   34.08   142   56.57   142   56.57
                                                                                                                                                                                                      
  Margin status          \<1.0 mm              18                2.57                            18                2.57                  16                3.56    16    3.56    2     0.80    2     0.80
                         1.00--4.99 mm         156               22.29                           223               31.86                 120               26.73   165   36.75   36    14.34   59    23.51
                         5.00--9.99 mm         67                9.57                                                                    45                10.02                 23    9.16           
                         ⩾10.00 mm             57                8.14                            57                8.14                  24                5.35    24    5.35    33    13.15   24    9.56
                         Clear                 205               29.29                                                                   111               24.72                 94    37.45          
                         Probably clear        43                6.14                                                                    24                5.35                  19    7.57           
                         Probably involved     32                4.57                            402               57.43                 26                5.79    244   54.34   6     2.39    158   62.95
                         Involved              57                8.14                                                                    51                11.36                 6     2.39           
                         Unknown               65                9.29                                                                    32                7.13                  33    13.15          

###### Adjuvant therapy for 700 cases with full treatment data

                                                **Conservation surgery**   **Mastectomy**   **All cases**                              
  --------------------------------------------- -------------------------- ---------------- --------------- ------- --------- -------- -----------------------------------
  **Treatment**                                 **No.**                    **%**            **No.**         **%**   **No.**   **%**    ***P***
  Surgery type                                  449                        64.14            251             35.86   700       100.00    
  No radiotherapy                               298                        66.37            243             96.81   541       77.29    \<0.00001
  Any radiotherapy[a](#t2-fn1){ref-type="fn"}   143                        31.85            4               1.59    147       21.00    \<0.00001
  Unknown Radiotherapy                          8                          1.78             4               1.59    12        1.71      
  Radiotherapy only                             36                         8.02             2               0.80    38        5.43     \<0.0001
  No hormone therapy                            189                        42.09            138             54.98   327       46.71    \<0.01[b](#t2-fn2){ref-type="fn"}
  Any hormone therapy^c^                        252                        56.12            106             42.23   358       51.14    \<0.0005
  Unknown hormone therapy                       8                          1.78             7               2.79    15        2.14      
  Hormone therapy only                          144                        32.07            104             41.43   248       35.43    \<0.05[b](#t2-fn3){ref-type="fn"}
  Radiotherapy+hormone therapy                  106                        23.61            2               0.80    108       15.43    \<0.00001
  Other combinations                            10                         2.23             7               2.79    17        2.43      
  Any known adjuvant therapy                    286                        63.70            108             43.03   394       56.29    \<0.00001
  No adjuvant therapy                           153                        34.08            136             54.18   289       41.29    \<0.00001

All cases of hormone therapy given are included in this table, no matter how long the hormone therapy was continued.

'Any radiotherapy\' includes patients who had radiotherapy alone or radiotherapy+hormone therapy or radiotherapy+unknown hormone therapy.

NS when corrected for multiple testing.

'Any hormone therapy\' includes patients who had hormone therapy alone or hormone therapy+radiotherapy or hormone therapy+unknown radiotherapy.

###### Number of first non-contralateral events and breast cancer deaths up to and including June 2010 diagnosed in the first 10 years of West Midlands Breast Screening programme between Apr 1988 and March 1998

                       **First \'non-contra-lateral event\'**        **Number and type of deaths**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
  ------------------- ---------------------------------------- ------------------------------------------ ------- ------------------- ------------------- ------------------ --------------------------------- ---------------------------------------------------------------------- -------------------------------------------------------------------------------------- -------------------------------------------------------------- ------------------------------------------------------------------ ------------------------------------- ------------------- ------------------------------------------------------------------- ------------------- -------------------------------------- ---------------------------- -------------------
  **Initial grade**               **No. of cases**              **No. of \'non-contra-lateral events\'**   **%**  **Type of event**    **No. of events**   **% with event**   **% of grade category overall**   **Deaths from breast cancer after one \'non contra-lateral event\'**   **Deaths from breast cancer after one non contra-lateral event**+**a further event**   **Deaths from breast cancer after bi-lateral further event**   **Deaths from breast cancer after contra-lateral further event**   **Total deaths from breast cancer**   **Mortality (%)**   **Number of non-cancer/other cancer/other breast primary deaths**   **Mortality (%)**   **Number of unknown cause of death**   **Deaths from all causes**   **Mortality (%)**
  Low                                    68                                        10                      14.7%  DCIS/Pagets                  4                40.00                      5.88                                                  0                                                                              0                                                                          0                                                                                                                     0                                                                                                                                                                                                             
                                                                                                                  Invasive                     6                60.00                      8.82                                                  0                                                                              0                                                                          0                                                                                                                     0                                                                                                                                                                                                             
                                                                                                                  Mets                         0                 0.00                      0.00                                                  0                                                                              0                                                                          0                                                                                                                     0                                                                                                                                                                                                             
                                                                                                                  all                         10                100.00                     14.71                                                 0                                                                              0                                                                          0                                                                0                                                    0                          0.00                                          8                                         11.76                          0                                 8                      11.76
  Intermediate                          174                                        28                      16.1%  DCIS/Pagets                 14                50.00                      8.05                                                  0                                                                              0                                                                          0                                                                                                                     0                                                                                                                                                                                                             
                                                                                                                  Invasive                     9                32.14                      5.17                                                  1                                                                              1                                                                          1                                                                                                                     3                                                                                                                                                                                                             
                                                                                                                  Mets                         5                17.86                      2.87                                                  3                                                                              0                                                                          0                                                                                                                     3                                                                                                                                                                                                             
                                                                                                                  all                         28                100.00                     16.09                                                 4                                                                              1                                                                          1                                                                0                                                    6                          3.45                                         16                                         9.20                           1                                 23                     13.22
  High                                  344                                        53                      15.4%  DCIS/Pagets                 29                54.72                      8.43                                                  0                                                                              1                                                                          0                                                                                                                     1                                                                                                                                                                                                             
                                                                                                                  Invasive                    22                41.51                      6.40                                                  1                                                                              4                                                                          1                                                                                                                     6                                                                                                                                                                                                             
                                                                                                                  Mets                         2                 3.77                      0.58                                                  1                                                                              1                                                                          0                                                                                                                     2                                                                                                                                                                                                             
                                                                                                                  all                         53                100.00                     15.41                                                 2                                                                              6                                                                          1                                                                1                                                   10                          2.91                                         49                                         14.24                          1                                 60                     17.44
  Unknown                               114                                        18                      15.8%  DCIS/Pagets                  6                33.33                      5.26                                                  0                                                                              0                                                                          0                                                                                                                     0                                                                                                                                                                                                             
                                                                                                                  Invasive                    12                66.67                      10.53                                                 2                                                                              6                                                                          0                                                                                                                     8                                                                                                                                                                                                             
                                                                                                                  Mets                         0                 0.00                      0.00                                                  0                                                                              0                                                                          0                                                                                                                     0                                                                                                                                                                                                             
                                                                                                                  all                         18                100.00                     15.79                                                 2                                                                              6                                                                          0                                                                1                                                    9                          7.89                                          8                                         7.02                           0                                 17                     14.91
  Total                                 700                                       109                      15.6%  DCIS/Pagets                 53                48.62                      7.57                                                  0                                                                              1                                                                          0                                                                                                                     1                                                                                                                                                                                                             
                                                                                                                  Invasive                    49                44.95                      7.00                                                  4                                                                              11                                                                         2                                                                                                                    17                                                                                                                                                                                                             
                                                                                                                  Mets                         7                 6.42                      1.00                                                  4                                                                              1                                                                          0                                                                                                                     5                                                                                                                                                                                                             
                                                                                                                  all                         109               100.00                     15.57                                                 8                                                                              13                                                                         2                                                                2                                                   25                          3.57                                         81                                         11.57                          2                                108                     15.43

###### Life tables for ipsilateral invasive recurrences up to 30 June 2010 from DCIS diagnosed in the West Midlands screening programme between April 1988 and March 1998

  ----------------------------- --------------------- ------------------------------- ------------------ -------------------
  **Time (months)**              **Number entering**   **Cumulative event rate (%)**   **Hazard rates**   **No recurrence**
                                                                                                                   
  *Breast-conserving surgery*                                                                            
   0                                     448                                                                       
   60                                    379                       11.8                     0.0002            88.2±1.5
   120                                   332                       17.1                     0.0007            82.9±1.8
   180                                   166                       21.5                     0.002             78.5±2.0
                                                                                                                   
  *Mastectomy*                                                                                           
   0                                     250                                                                       
   60                                    234                        3.1                     0.0007            96.9±1.1
   120                                   218                        5.6                     0.0004            94.4±1.4
   180                                   89                          8                       0.01             92.0±1.8
                                                                                                                   
  *Total*                                                                                                
   0                                     700                                                                       
   60                                    613                        8.6                     0.0004            91.4±1.3
   120                                   550                       12.6                     0.0006            87.4±1.6
   180                                   255                        16                      0.0016            84.0±1.9
  ----------------------------- --------------------- ------------------------------- ------------------ -------------------

###### Histological grade of ipsilateral invasive recurrences up to and including December 2010 from DCIS diagnosed in the West Midlands screening programme between April 1988 and March 1998 by initial DCIS grade

                             **Ipsilateral invasive recurrence (all events)** **Grade**                                                                                        
  ------------------------- ------------------------------------------------------------ --------- ------- --------- --------- --------- ------- --------- ------- ----------- --------------------------
                                                                                           **I**   **2**   **3**     **N/K**                                                   
  **Original DCIS grade**                             **No.**                             **No.**  **%**   **No.**   **%**     **No.**   **%**   **No.**   **%**    **Total**   **Breast cancer deaths**
  Low                                                    68                                  2     33.3%   2         33.3%     0         0.0%    2         33.3%        6                  0
  Intermediate                                          174                                  0     0.0%    4         36.4%     5         45.5%   2         18.2%       11                  3
  High                                                  344                                  1     4.0%    10        40.0%     8         32.0%   6         24.0%       25                  7
  Not known                                             114                                  0     0.0%    6         50.0%     5         41.7%   1         8.3%        12                  8
  Total                                                 700                                  3     5.6%    22        40.7%     18        33.3%   11        20.4%       54                  18
